|
RAB1A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62436730732907E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.11022302462516E-15 |
| Normal-vs-Stage2 |
4.91510054878574E-10 |
| Normal-vs-Stage3 |
<1E-12 |
| Normal-vs-Stage4 |
1.62436730732907E-12 |
| Stage1-vs-Stage2 |
5.289400E-01 |
| Stage1-vs-Stage3 |
3.315500E-02 |
| Stage1-vs-Stage4 |
2.24250000002701E-06 |
| Stage2-vs-Stage3 |
5.995900E-02 |
| Stage2-vs-Stage4 |
1.156060E-03 |
| Stage3-vs-Stage4 |
2.061800E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
4.02560000001273E-07 |
| Normal-vs-Asian |
7.7715611723761E-16 |
| Caucasian-vs-AfricanAmerican |
5.541600E-01 |
| Caucasian-vs-Asian |
8.157200E-01 |
| AfricanAmerican-vs-Asian |
6.285400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
4.554000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62470037423645E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(81-100Yrs) |
3.233000E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.603200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.384400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.588800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.710600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.511600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.900200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.177850E-03 |
| Classical-VS-Follicular |
1.394150E-01 |
| Classical-VS-Other |
3.358800E-01 |
| Classical-VS-Normal |
1.11022302462516E-15 |
| Tall-VS-Follicular |
2.838200E-04 |
| Tall-VS-Other |
7.959400E-01 |
| Tall-VS-Normal |
1.62447832963153E-12 |
| Follicular-VS-Other |
2.268600E-01 |
| Follicular-VS-Normal |
4.5914383406398E-12 |
| Other-VS-Normal |
1.74045999999928E-05 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.22044604925031E-16 |
| Normal-vs-N1 |
<1E-12 |
| N0-vs-N1 |
6.062800E-03 |
|
|
